• Activity INFORMATION

  Overview

  As many as 1 in 200 hospitalized children may experience a thromboembolic event. Since there are no FDA approved parenteral anticoagulant therapies for the pediatric population,  pharmacists may be unfamiliar or uncomfortable with the treatment options. This program will educate pharmacists, nurses, and pharmacy technicians on the direct thrombin inhibitors, argatroban and bivalirudin, as alternatives to heparin for the treatment of pediatric thromboembolism. It will cover the challenges of heparin use in pediatrics as well as the advantages, disadvantages, dosing, and monitoring of bivalirudin and argatroban. 
  

  Handouts

  • Homestudy PDF :   19066H01.pdf Download

  Financial Support By

  PharmCon

• Learning OBJECTIVES

  Pharmacist

  Identify the challenges associated with the use of heparin in pediatric patients.

  Describe dosing and monitoring of argatroban in pediatric patients, based on a dose finding, safety and efficacy study in pediatric patients.

  Describe dosing and monitoring of bivalirudin in pediatric patients, based on two dose-finding, safety and efficacy studies in pediatric patients.

  Describe the advantages and disadvantages of the use of direct thrombin inhibitors in pediatric patients.

  Pharmacy Technician

  Describe the advantages and disadvantages of the use of direct thrombin inhibitors in pediatric patients.

  Identify the challenges associated with the use of heparin in pediatric patients.

  Recognize dosing and monitoring of argatroban in pediatric patients, based on a dose finding, safety and efficacy study in pediatric patients.

  Recognize dosing and monitoring of bivalirudin in pediatric patients, based on two dose-finding, safety and efficacy studies in pediatric patients.

  Nurse

  Describe dosing and monitoring of bivalirudin in pediatric patients, based on two dose-finding, safety and efficacy studies in pediatric patients.

  Identify the challenges associated with the use of heparin in pediatric patients.

  Describe the advantages and disadvantages of the use of direct thrombin inhibitors in pediatric patients.

  Describe dosing and monitoring of argatroban in pediatric patients, based on a dose finding, safety and efficacy study in pediatric patients.

• Activity ACCREDITATION

  Activity Type

  Knowledge

  CE Broker

  20-652589

  Universal Activity Number

  Pharmacist 0798-0000-19-066-H01-P
  Pharmacy Technician 0798-0000-19-066-H01-T
  Nurse 0798-0000-19-066-H01-N
  

  PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

  PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

  In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.

• Activity INSTRUCTION

  Faculty

  Chasity  Shelton, PharmD, FCCP, BCPS, BCPPS Associate Professor of Clinical Pharmacy & Translational Science; University of Tennessee Health Science Center

  Nikita  Morse, Inspector/Agent DHEC

This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).